Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Active surveillance study of hematologic toxicity of fluzoparib in ovarian cancer
ChiCTR2300078644Phase 4Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluzoparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: Adverse events. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
fluzoparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2300078644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078644.